首页> 外文期刊>Stem cells translational medicine. >Patient-Derived Human Induced Pluripotent Stem Cells From Gingival Fibroblasts Composited With Defined Nanohydroxyapatite/Chitosan/Gelatin Porous Scaffolds as Potential Bone Graft Substitutes
【24h】

Patient-Derived Human Induced Pluripotent Stem Cells From Gingival Fibroblasts Composited With Defined Nanohydroxyapatite/Chitosan/Gelatin Porous Scaffolds as Potential Bone Graft Substitutes

机译:患者牙龈成纤维细胞与定义的纳米羟基磷灰石/壳聚糖/明胶多孔支架复合作为潜在的骨移植替代物的患者诱导的人多能干细胞。

获取原文
           

摘要

Human embryonic stem cells and adult stem cells have always been the cell source for bone tissue engineering. However, their limitations are obvious, including ethical concerns and/or a short lifespan. The use of human induced pluripotent stem cells (hiPSCs) could avoid these problems. Nanohydroxyapatite (nHA) is an important component of natural bone and bone tissue engineering scaffolds. However, its regulation on osteogenic differentiation with hiPSCs from human gingival fibroblasts (hGFs) is unknown. The purpose of the present study was to investigate the osteogenic differentiation of hiPSCs from patient-derived hGFs regulated by nHA/chitosan/gelatin (HCG) scaffolds with different nHA ratios, such as HCG-111 (1 wt/vol% nHA) and HCG-311 (3 wt/vol% nHA). First, hGFs were reprogrammed into hiPSCs, which have enhanced osteogenic differentiation capability. Second, HCG-111 and HCG-311 scaffolds were successfully synthesized. Finally, hiPSC/HCG complexes were cultured in vitro or subcutaneously transplanted into immunocompromised mice in vivo. The osteogenic differentiation effects of two types of HCG scaffolds on hiPSCs were assessed for up to 12 weeks. The results showed that HCG-311 increased osteogenic-related gene expression of hiPSCs in vitro proved by quantitative real-time polymerase chain reaction, and hiPSC/HCG-311 complexes formed much bone-like tissue in vivo, indicated by cone-beam computed tomography imaging, H&E staining, Masson staining, and RUNX-2, OCN immunohistochemistry staining. In conclusion, our study has shown that osteogenic differentiation of hiPSCs from hGFs was improved by HCG-311. The mechanism might be that the nHA addition stimulates osteogenic marker expression of hiPSCs from hGFs. Our work has provided an innovative autologous cell-based bone tissue engineering approach with soft tissues such as clinically abundant gingiva.The present study focused on patient-personalized bone tissue engineering. Human induced pluripotent stem cells (hiPSCs) were established from clinically easily derived human gingival fibroblasts (hGFs) and defined nanohydroxyapatite/chitosan/gelatin (HCG) scaffolds. hiPSCs derived from hGFs had better osteogenesis capability than that of hGFs. More interestingly, osteogenic differentiation of hiPSCs from hGFs was elevated significantly when composited with HCG-311 scaffolds in vitro and in vivo. The present study has uncovered the important role of different nHA ratios in HCG scaffolds in osteogenesis induction of hiPSCs derived from hGFs. This technique could serve as a potential innovative approach for bone tissue engineering, especially large bone regeneration clinically.
机译:人类胚胎干细胞和成年干细胞一直是骨组织工程的细胞来源。但是,它们的局限性显而易见,包括道德问题和/或使用寿命短。使用人类诱导的多能干细胞(hiPSC)可以避免这些问题。纳米羟基磷灰石(nHA)是天然骨和骨组织工程支架的重要组成部分。但是,它对人类牙龈成纤维细胞(hGFs)的hiPSC对成骨分化的调控尚不清楚。本研究的目的是研究hiPSCs与患者来源的hGFs的成骨分化,这些hGFs受nHA /壳聚糖/明胶(HCG)支架的调节,具有不同的nHA比例,例如HCG-111(1 wt / vol%nHA)和HCG -311(3 wt / vol%nHA)。首先,将hGFs重新编程为hiPSCs,它们具有增强的成骨分化能力。其次,成功合成了HCG-111和HCG-311支架。最后,hiPSC / HCG复合物在体外培养或体内皮下移植到免疫功能低下的小鼠体内。评估了长达12周的两种HCG支架对hiPSC的成骨分化作用。结果显示,通过实时定量聚合酶链反应证明,HCG-311可增加hiPSCs的成骨相关基因表达,而hiPSC / HCG-311复合物可在体内形成许多骨样组织,如锥形束计算机断层扫描所示成像,H&E染色,Masson染色以及RUNX-2,OCN免疫组织化学染色。总之,我们的研究表明,HCG-311可改善hPS中hiPSC的成骨分化。其机制可能是nHA的添加刺激了hGF中hiPSC的成骨标记表达。我们的工作提供了一种创新的基于自体细胞的骨组织工程方法,包括软组织(例如临床上丰富的牙龈)。本研究的重点是患者个性化的骨组织工程。从临床上容易衍生的人牙龈成纤维细胞(hGFs)和确定的纳米羟基磷灰石/壳聚糖/明胶(HCG)支架建立了人诱导的多能干细胞(hiPSC)。来自hGF的hiPSC比hGF具有更好的成骨能力。更有趣的是,当在体外和体内与HCG-311支架复合时,hiPSC从hGF的成骨分化显着提高。本研究揭示了HCG支架中不同的nHA比率在衍生自hGF的hiPSC的成骨诱导中的重要作用。该技术可以作为骨组织工程,特别是临床上大型骨再生的潜在创新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号